Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
作者信息
Long G V, Flaherty K T, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen J B A G, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies M A, Lane S R, Legos J J, Mookerjee B, Grob J-J
出版信息
Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221.
Abstract
摘要
相似文献
1
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.达拉非尼联合曲美替尼与达拉非尼单药治疗转移性BRAF V600E/K突变黑色素瘤患者：一项3期研究的长期生存和安全性分析
Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221.
2
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.达拉非尼联合曲美替尼与达拉非尼单药治疗转移性BRAF V600E/K突变黑色素瘤患者：一项3期研究的长期生存和安全性分析
Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176.
3
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF or BRAF mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.接受辅助达拉非尼联合曲美替尼治疗的切除后高风险黑色素瘤伴 BRAF 或 BRAF 突变患者的患者报告结局（COMBI-AD）：一项随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.
4
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.达拉非尼联合曲美替尼治疗 BRAF V600E 突变型甲状腺未分化癌患者：来自 II 期 ROAR 篮子研究的更新分析。
Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10.
5
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.新辅助加辅助达拉非尼和曲美替尼与高危可切除黑色素瘤患者的标准治疗相比：一项单中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.
6
Trametinib: a MEK inhibitor for management of metastatic melanoma.曲美替尼：一种用于治疗转移性黑色素瘤的MEK抑制剂。
Onco Targets Ther. 2015 Aug 25;8:2251-9. doi: 10.2147/OTT.S72951. eCollection 2015.
7
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.达拉非尼联合曲美替尼治疗既往未经治疗的 BRAF 突变型转移性非小细胞肺癌的开放标签、2 期临床试验。
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
8
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.接受单药达布拉非尼治疗的 BRAF V600 突变型转移性黑色素瘤患者的长期结局：来自 2 期和 3 期临床试验的分析。
Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033.
9
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.达拉非尼联合曲美替尼，或单药用于治疗 BRAF 突变型转移性黑色素瘤。
Clin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28.
10
Adverse Event Management in Patients with V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.V600E 突变型非小细胞肺癌患者接受达拉非尼联合曲美替尼治疗的不良事件管理。
Oncologist. 2019 Jul;24(7):963-972. doi: 10.1634/theoncologist.2018-0296. Epub 2018 Dec 31.
引用本文的文献
1
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.液体活检中循环肿瘤DNA的检测：当前技术及其在黑色素瘤中的潜在应用
Int J Mol Sci. 2025 Jan 20;26(2):861. doi: 10.3390/ijms26020861.
2
Precision Oncology in Melanoma: Changing Practices.黑色素瘤的精准肿瘤学：不断变化的实践
J Nucl Med. 2024 Dec 3;65(12):1838-1845. doi: 10.2967/jnumed.124.267781.
3
A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.细胞质突变型 p53（E285K）赋予恶性黑色素瘤的化疗耐药性。
Cell Death Dis. 2023 Dec 14;14(12):831. doi: 10.1038/s41419-023-06360-4.
4
Association of CDKN2A alterations with increased postoperative seizure risk after resection of brain metastases.CDKN2A 改变与脑转移瘤切除术后癫痫发作风险增加的相关性。
Neurosurg Focus. 2023 Aug;55(2):E14. doi: 10.3171/2023.5.FOCUS23133.
5
Current Patterns of Treatment and Outcomes in Advanced Melanoma at a Single Institution.单中心晚期黑色素瘤的治疗现状和预后。
J Surg Res. 2023 Nov;291:25-33. doi: 10.1016/j.jss.2023.05.024. Epub 2023 Jun 16.
6
BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.脑肿瘤中的 BRAF 突变——预后标志物和治疗靶点。
CNS Drugs. 2023 Jul;37(7):587-598. doi: 10.1007/s40263-023-01016-5. Epub 2023 Jun 2.
7
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.新辅助联合辅助使用维莫非尼、考比替尼和阿特珠单抗治疗高危、可切除的BRAF突变和野生型黑色素瘤患者：NEO-TIM，一项II期随机非对照研究
Front Oncol. 2023 Feb 9;13:1107307. doi: 10.3389/fonc.2023.1107307. eCollection 2023.
8
Targeted Therapy for Melanomas Without BRAF V600 Mutation.无 BRAF V600 突变黑色素瘤的靶向治疗。
Curr Oncol Rep. 2022 Dec;24(12):1873-1881. doi: 10.1007/s11912-022-01306-z. Epub 2022 Nov 26.
9
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.晚期皮肤黑色素瘤患者在BRAFi/MEKi联合治疗后使用抗PD1免疫疗法的长期结果和预后生物标志物
Cancers (Basel). 2022 Apr 24;14(9):2123. doi: 10.3390/cancers14092123.
10
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.国际主要转诊中心间前哨淋巴结阳性黑色素瘤行完全淋巴结清扫术和辅助全身治疗的应用的中心水平差异。
Ann Surg. 2023 May 1;277(5):e1106-e1115. doi: 10.1097/SLA.0000000000005370. Epub 2023 Apr 6.
Zotero 插件